CASE CCC IN THE NEWS
Tivozanib for Kidney Cancer Rejected by FDA
Medscape - Jun 11, 2013
At the ODAC meeting, 1 of the committee members Mikkael Sekeres MD, MS, associate professor of medicine at the Cleveland Clinic Taussig Cancer Institute, in Ohio, said it would be difficult to explain these results to a patient.
Cleveland Cancer Researchers Host Policy Forum on Genomics and Cancer Treatment
The Plain Dealer - Jun 10, 2013
More than 200 people - oncologists and researchers from 17 universities and cancer centers in 13 states, patient advocacy groups, pharmaceutical and biotechnology company representatives - are in Cleveland today for a day-long dialogue on genomics and its impact on the diagnosis and treatment of cancer..."We have the ability to fingerprint each person's cancer at many points along the way, so we can target a treatment specifically for that person's tumor, so it's much more precise and much more exact," said Dr. Stanton Gerson, director of Case Comprehensive Cancer Center, which includes the Cleveland Clinic Taussig Cancer Institute and University Hospitals Seidman Cancer Center.
Bright Pink Cleveland Reaches Out to Young Women at High Risk for Hereditary Breast and Ovarian Cancer
The Plain Dealer - Jun 10, 2013
"We can bring everything together in one place," said Dr. Robert Shenk, medical director of the Breast Center at UH Case Medical Center and associate professor of surgery at Case Western Reserve University School of Medicine, who oversees the new center.
ASCO 2013 Myelodysplastic Syndromes Update - Day Three: Education Session
MDS Beacon - Jun 5, 2013
Dr. Mikkael Sekeres from the Cleveland Clinic gave the final talk of the education session. He spoke about the diagnosis and treatment of patients with MDS / myeloproliferative neoplasm (MPN) overlap disorders, such as chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (CML), and refractory anemia with ring sideroblasts - thrombocytosis (RARS-T).
Analysis: New Cancer Breakthroughs Add Pressure to Control Costs
Yahoo Health - Jun 4, 2013
Insurers "are paying more attention to the appropriate use of interventions - there are more pre-reviews and less flexibility in 'off-label' use," said Dr. Neal Meropol, chief of the division of hematology and oncology at University Hospitals Case Medical Center in Cleveland. He was referring to the practice of prescribing drugs for uses not specifically approved by regulators.
Fine-Tuning Breast Cancer Treatments: What Works Better?
US News & World Report - Jun 3, 2013
Two common schedules used for the chemotherapy paclitaxel (Taxol) are equally effective at controlling breast cancer, but fewer side effects are found with the weekly regimen rather than every two weeks, according to a new study...The estimated five-year progression-free survival rates were the same for both groups, said Dr. G. Thomas Budd, who led the study.
Dr. DiFeo Receives Funding from Mary Kay Foundation
Mary Kay Foundation for her project,Single Agent Dual Inhibition of the AKT and ERK Signaling Pathway for the Treatment of Ovarian Cancer.
PREVIOUSLY ANNOUNCED OPPORTUNITIES
OCRP Ovarian Cancer Academy Award - Early-Career Investigator
OCRP Resource Development Award
AACR Scholar-in-Training Awards - Other Conferences and Meetings
NIH BULLETIN – Notices and Funding Opportunities
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!
Send items to email@example.com.